$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Phase III clinical trial of dacomitinib in the treatment of locally advanced or metastatic non-small cell lung cancer carrying EGFR_ Kanghule
2025-10-19 11:44:20
Check Details
What are the differences between the second-generation targeted drug for lung cancer, dacomitinib, and the first-generation drug?
2025-10-19 11:44:20
Check Details
Effects and effects of crizotinib (Xalkori) on ROS1 mutated lung cancer
2025-10-19 11:44:20
Check Details
Cabozantinib (XL184) is a potent ROS1 inhibitor_ Kangxi
2025-10-19 11:44:20
Check Details
How about crizotinib (Xalkori) in treating lung cancer?
2025-10-19 11:44:20
Check Details
Does the targeted drug vandetanib have an effect on patients with RET mutations in lung cancer?
2025-10-19 11:44:20
Check Details
Which patients with lung cancer can vandetanib be used to treat?
2025-10-19 11:44:20
Check Details
Ramucirumab + docetaxel for metastatic non-small cell lung cancer that worsens during or after platinum-containing chemotherapy_ Kanghule
2025-10-19 11:44:20
Check Details
How much does a box of Vandetanib cost? Where can I buy it in China?
2025-10-19 11:44:20
Check Details
The effect and toxic side effects of vandetanib in the treatment of lung cancer with specific gene mutations
2025-10-19 11:44:20
Check Details
Data on ramucirumab in the treatment of metastatic non-small cell lung cancer with EGFR gene mutations
2025-10-19 11:44:20
Check Details
Vandetanib can effectively improve the median progression-free survival of lung cancer with specific gene mutations
2025-10-19 11:44:20
Check Details
1
2
...
3885
3886
3887
3888
3889
3890
3891
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
2
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
3
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
4
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
5
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
6
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
7
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
8
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
9
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
10
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
11
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
12
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer